Lupin launches generic equivalent of Bumex Injection in US
Mumbai: Global pharma major Lupin Limited (Lupin) announced on Tuesday the launch of Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multiple-Dose Vials in the United States, after having received an approval from the United Food and Drug Administration (U.S. FDA).
Bumetanide Injection USP, is a generic equivalent of Bumex® Injection, 0.25 mg/mL of Validus Pharmaceuticals, LLC., indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.
Bumetanide Injection USP (RLD Bumex®) had an estimated annual sale of USD 20 million in the U.S. (IQVIA MAT September 2024).
Also Read: Lupin bags tentative USFDA nod for Raltegravir Tablets for HIV-1 infection
Lupin Limited is headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals.
Also Read: Natco Pharma names Imtiyaz Basade as Senior Vice President - RAD, Pharma Division, Kothur Unit
